Birchview Capital, LP
- SEC CIK
- 0001618205
- Latest filing
- Aug 14, 2026
KROS holding history
Keros Therapeutics, Inc. in every 13F filed by Birchview Capital, LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
KROS overviewAll 13F holders of KROSFull Q2 2026 holdings
- Shares (Q2 2025)
- 0
- Sold out in Q2 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 10
- Since Q4 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2025 | 0 | $0 | 0.0% | −15,000−100.0% | Sold out | Holders |
| Q1 2025 | 15,000 | $152.8K | 0.1% | 00.0% | Unchanged | Holders |
| Q4 2024 | 15,000 | $237.4K | 0.2% | +8,000+114.3% | Added | Holders |
| Q3 2024 | 7,000 | $406.5K | 0.4% | 00.0% | Unchanged | Holders |
| Q2 2024 | 7,000 | $319.9K | 0.3% | 00.0% | Unchanged | Holders |
| Q1 2024 | 7,000 | $463.4K | 0.4% | 00.0% | Unchanged | Holders |
| Q4 2023 | 7,000 | $278.3K | 0.2% | 00.0% | Unchanged | Holders |
| Q3 2023 | 7,000 | $223.2K | 0.2% | 00.0% | Unchanged | Holders |
| Q2 2023 | 7,000 | $281.3K | 0.2% | 00.0% | Unchanged | Holders |
| Q1 2023 | 7,000 | $299.0K | 0.2% | 00.0% | Unchanged | Holders |
| Q4 2022 | 7,000 | $336.0K | 0.2% | +7,000 | New | Holders |